Public offering

Software Acquisition Group Inc. II Announces Pricing of $150,000,000 Initial Public Offering

Retrieved on:

Tuesday, September 15, 2020

Corporate finance, Financial economics, Finance, Financial markets, Initial public offering, Stock market, Options, Warrant, Public offering, Security, Offering

New York, NY, Sept. 14, 2020 (GLOBE NEWSWIRE) -- Software Acquisition Group Inc. II (the Company) announced today that it priced its initial public offering of 15,000,000 units, at $10.00 per unit.

Key Points:

New York, NY, Sept. 14, 2020 (GLOBE NEWSWIRE) -- Software Acquisition Group Inc. II (the Company) announced today that it priced its initial public offering of 15,000,000 units, at $10.00 per unit.
No fractional warrants will be issued upon separation of the units and only whole warrants will trade.
The Company has granted B. Riley Securities, Inc. a 45-day option to purchase up to an additional 2,250,000 units at the initial public offering price to cover over-allotments, if any.
This press release contains statements that constitute forward-looking statements, including with respect to the initial public offering and the anticipated use of the net proceeds.

89bio Announces Proposed Public Offering of Common Stock

Retrieved on:

Monday, September 14, 2020

Finance, Financial economics, Stock market, Money, Corporate finance, Initial public offering, Financial markets, SVB Leerink, Underwriting, Stock, Public offering, Security

In addition, the company and a selling stockholder is expected to grant the underwriters of the offering an option for a period of 30 days to purchase up to an additional 175,000 shares of common stock and 275,000 shares of common stock, respectively, at the public offering price, less the underwriting discounts and commissions.

Key Points:

In addition, the company and a selling stockholder is expected to grant the underwriters of the offering an option for a period of 30 days to purchase up to an additional 175,000 shares of common stock and 275,000 shares of common stock, respectively, at the public offering price, less the underwriting discounts and commissions.
The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.
BofA Securities, SVB Leerink and RBC Capital Markets are acting as lead book-running managers for the offering.
89bio claims the protection of the Safe Harbor contained in the Private Securities Litigation Reform Act of 1995 for forward-looking statements.

Nyxoah Initial Public Offering Multiple Times Over Subscribed and Early Closing Announced

Retrieved on:

Monday, September 14, 2020

Initial public offering, Financial markets, Financial economics, Finance, Stock market, Corporate finance, Prospectus, Security, Public offering, Red herring prospectus, Regulation S-K

The information contained in this announcement is for informational purposes only and does not purport to be full or complete.

Key Points:

The information contained in this announcement is for informational purposes only and does not purport to be full or complete.
Investors should not subscribe for any securities referred to in this document except on the basis of information contained in the Prospectus.
No public offering of securities is being made in the United States.
Potential investors should consult a professional advisor as to the suitability of the intended offering for the person concerned.

Corsair Gaming, Inc. Launches Initial Public Offering

Retrieved on:

Monday, September 14, 2020

Corsair Gaming, Inc. (Corsair), a leading global provider and innovator of high-performance gear for gamers and content creators, announced today that it has commenced an initial public offering of 14,000,000 shares of its common stock, approximately 7,500,000 of which are being offered by Corsair and approximately 6,500,000 of which are being offered by a selling stockholder.

Key Points:

Corsair Gaming, Inc. (Corsair), a leading global provider and innovator of high-performance gear for gamers and content creators, announced today that it has commenced an initial public offering of 14,000,000 shares of its common stock, approximately 7,500,000 of which are being offered by Corsair and approximately 6,500,000 of which are being offered by a selling stockholder.
The initial public offering price is estimated to be between $16.00 and $18.00 per share.
Corsair has applied to list its common stock on the Nasdaq Global Market under the ticker symbol CRSR.
The offering is subject to market conditions, and there can be no assurance as to whether, or when, the offering may be completed or as to the actual size or terms of the offering.

The Law Offices of Frank R. Cruz Announces the Filing of a Securities Class Action on Behalf of YayYo, Inc. (YAYO) Investors

Retrieved on:

Friday, September 11, 2020

Legal, Professional services, Finance, Financial economics, Corporate finance, Stock market, Initial public offering, Financial markets, Stock, NASDAQ, Public offering

YayYo investors have until November 9, 2020 to file a lead plaintiff motion.

Key Points:

YayYo investors have until November 9, 2020 to file a lead plaintiff motion.
In November 2019, YayYo completed its initial public offering (IPO), in which it sold approximately 2.7 million shares of common stock at $4 per share.
Then, on February 10, 2020, the Company announced that its Board of Directors had decided to delist YayYos common stock from the NASDAQ.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

Spero Therapeutics Announces Pricing of Securities Offering

Retrieved on:

Friday, September 11, 2020

Initial public offering, Finance, Financial economics, Money, Corporate finance, Actuarial science, Underwriting, Stock market, Spero, Public offering

The gross proceeds to Spero from this offering are expected to be $80.0 million, before deducting underwriting discounts and commissions and other estimated offering expenses payable by Spero.

Key Points:

The gross proceeds to Spero from this offering are expected to be $80.0 million, before deducting underwriting discounts and commissions and other estimated offering expenses payable by Spero.
All of the securities in the offering are being sold by Spero.
In addition, Spero has granted the underwriters in the offering a 30-day option to purchase up to an additional 1,200,000 shares of common stock at the public offering price, less the underwriting discounts and commissions.
Oppenheimer & Co. Inc. is acting as lead manager for the offering, and H.C. Wainwright & Co., LLC is acting as co-manager for the offering.

10x Genomics Announces Pricing of Upsized Public Offering

Retrieved on:

Friday, September 11, 2020

Financial markets, Finance, Financial economics, Initial public offering, Stock market, Corporate finance, Actuarial science, Underwriting, 10x Genomics, Public offering, Security

PLEASANTON, Calif., Sept. 10, 2020 (GLOBE NEWSWIRE) -- 10x Genomics, Inc. (NASDAQ: TXG) (the Company) today announced the pricing of an upsized underwritten public offering by the Company of its Class A common stock at a price to the public of $110.00 per share, before underwriting discounts and commissions.

Key Points:

PLEASANTON, Calif., Sept. 10, 2020 (GLOBE NEWSWIRE) -- 10x Genomics, Inc. (NASDAQ: TXG) (the Company) today announced the pricing of an upsized underwritten public offering by the Company of its Class A common stock at a price to the public of $110.00 per share, before underwriting discounts and commissions.
10x Genomics is offering 4,000,000 shares of its Class A common stock, plus up to an additional 600,000 shares of its Class A common stock that the underwriters have the right to purchase at the public offering price, less the underwriting discounts and commissions.
The offering is expected to close on September 15, 2020, subject to customary closing conditions.
The offering is being made through an underwriting group led by J.P. Morgan Securities LLC, BofA Securities and Cowen and Company, LLC.

Quotient Limited Announces Upsize and Pricing of Underwritten Offering of Ordinary Shares

Retrieved on:

Friday, September 11, 2020

Finance, Money, Financial economics, Corporate finance, Economy of New York City, NASDAQ, Trademark, Public offering

JERSEY, Channel Islands, Sept. 10, 2020 (GLOBE NEWSWIRE) -- Quotient Limited (NASDAQ: QTNT) (the Company), a commercial-stage diagnostics company, today announced the upsize and pricing of a $75 million underwritten public offering.

Key Points:

JERSEY, Channel Islands, Sept. 10, 2020 (GLOBE NEWSWIRE) -- Quotient Limited (NASDAQ: QTNT) (the Company), a commercial-stage diagnostics company, today announced the upsize and pricing of a $75 million underwritten public offering.
The Company is offering 17,647,059 ordinary shares at a price to the public of $4.25 per share.
All of the ordinary shares sold in the offering were offered by the Company.
The Quotient logo, Quotient MosaiQ and MosaiQ are trademarks or registered trademarks of Quotient Limited or its subsidiaries in various jurisdictions.

Intra-Cellular Therapies Prices Public Offering of Common Stock

Retrieved on:

Friday, September 11, 2020

Financial economics, Corporate finance, Financial markets, Finance, Stock market, Initial public offering, Stock, Public offering, Catabasis Pharmaceuticals

NEW YORK, Sept. 10, 2020 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc.(Nasdaq: ITCI), a biopharmaceutical company, today announced the pricing of its previously announced underwritten public offering of 11,666,667 shares of its common stock at a public offering price of $30.00 per share.

Key Points:

NEW YORK, Sept. 10, 2020 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc.(Nasdaq: ITCI), a biopharmaceutical company, today announced the pricing of its previously announced underwritten public offering of 11,666,667 shares of its common stock at a public offering price of $30.00 per share.
All of the shares in the offering will be sold by Intra-Cellular Therapies, with gross proceeds to Intra-Cellular Therapies expected to be $350 million from the offering of an aggregate of 11,666,667 shares before deducting underwriting discounts and commissions and offering expenses.
The offering is expected to close on September 15, 2020, subject to the satisfaction of customary closing conditions.
Forward-looking statements include statements, other than statements of historical fact, regarding, among other things, the completion and timing of the public offering and the anticipated total gross proceeds from the offering.

i3 Verticals, Inc. Prices Public Offering of Class a Common Stock

Retrieved on:

Friday, September 11, 2020

Technology, Finance, Consulting, Professional services, Software, Other Education, Internet, Data management, Education, Financial economics, Finance, Corporate finance, Initial public offering, Stock market, Financial markets, Stock, Underwriting, Public offering

i3 Verticals, Inc. (Nasdaq: IIIV) (the Company) today announced the pricing of its public offering of 3,250,000 shares of Class A common stock at a public offering price of $23.50 per share.

Key Points:

i3 Verticals, Inc. (Nasdaq: IIIV) (the Company) today announced the pricing of its public offering of 3,250,000 shares of Class A common stock at a public offering price of $23.50 per share.
In addition, the Company has granted the underwriters a 30-day option to purchase up to an additional 487,500 shares of Class A common stock, at the public offering price, less the underwriting discount.
The Company anticipates that the gross proceeds from the offering will be $76.4 million, before deducting the underwriting discount and estimated offering expenses.
The Company intends to use the net proceeds from the sale of 3,250,000 shares of Class A common stock in the offering (approximately $72.1 million) for general corporate purposes, including to repay outstanding indebtedness and to fund strategic acquisition opportunities.